U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
[ X ] QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended September 30, 2003
[ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ___________ to _____________
Commission file number: 001-16253
COMPUTERIZED THERMAL IMAGING, INC.
-----------------------------------------------------
(Exact name of Registrant as specified in its charter)
NEVADA 87-0458721
----------------------------------- --------------------------
(State or other jurisdiction of incorporation or (IRS Employer
organization) Identification No.)
1719 West 2800 South
Ogden, Utah 84401
----------------------------------- ----------------
(Address of principal executive offices) (Zip Code)
(801) 776-4700
------------------------
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Exchange Act during the
preceding 12 months (or for such shorter period that the registrant was required
to file such reports) and (2) has been subject to such filing requirements for
the past 90 days. Yes [ X ] No [ ]
Indicate by check mark whether the registrant is an accelerated filer
(as defined in Rule 12b-2 of the Exchange Act). Yes [ ] No [ X ]
Indicate the number of shares outstanding of each of the issuer's
classes of common stock, as of the latest practicable date: Common stock, par
value $0.001, of which 112,870,031 shares were issued and outstanding as of
October 30, 2003.
COMPUTERIZED THERMAL IMAGING, INC.
FORM 10-Q
QUARTERLY REPORT
TABLE OF CONTENTS
PART I - FINANCIAL INFORMATION
ITEM 1. Financial Statements...................................................2
Condensed Consolidated Balance Sheets as of September 30, 2003
and June 30, 2003 ....................................................2
Condensed Consolidated Statements of Operations and Other
Comprehensive Income (Loss) for the three months ended September
30, 2003 and 2002 and for the period from inception on
June 10, 1987 to September 30, 2003 ..................................3
Condensed Consolidated Statements of Cash Flows for the three
months ended September 30, 2003 and 2002 and for the period from
inception on June 10, 1987 to September 30, 2003 .....................4
Notes to Condensed Consolidated Financial Statements..................6
ITEM 2. Management's Discussion and Analysis of Financial Condition and
Results of Operations.................................................15
ITEM 3. Quantitative and Qualitative Disclosures About Market Risk............26
ITEM 4. Controls and Procedures...............................................27
PART II - OTHER INFORMATION
ITEM 1. Legal Proceedings.....................................................27
ITEM 2. Changes in Securities.................................................29
ITEM 3. Defaults upon Senior Securities.......................................30
ITEM 6. Exhibits and Reports on Form 8-K......................................31
SIGNATURES....................................................................32
i
PART I - FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
COMPUTERIZED THERMAL IMAGING, INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(A Development Stage Company)
September 30, June 30,
2003 2003
------------- -------------
ASSETS (Unaudited)
CURRENT ASSETS:
Cash and cash equivalents $ 1,210,645 $ 454,387
Investments available for sale -- --
Accounts receivable-trade, net (less allowance for doubtful
accounts of $66,231 and $3,199 for September 30, 2003
and June 30, 2003, respectively) 29,011 420,395
Accounts receivable-other, net -- --
Inventories 333,710 305,864
Prepaid expenses 191,980 310,248
------------- -------------
Total current assets 1,765,346 1,490,894
------------- -------------
PROPERTY AND EQUIPMENT, NET 254,574 312,719
------------- -------------
INTANGIBLE ASSETS:
Intellectual property rights, net (less accumulated amortization of
accounts of $15,449 and $14,997 for September 30, 2003
and June 30, 2003, respectively) 17,398 18,065
------------- -------------
TOTAL ASSETS $ 2,037,318 $ 1,821,678
============= =============
LIABILITIES AND STOCKHOLDERS' EQUITY (DEFICIT)
CURRENT LIABILITIES:
Accounts payable $ 631,059 $ 655,075
Accrued liabilities 377,753 406,032
Accrued settlement reserve 100,000 100,000
Convertible debenture -- 157,276
Deferred revenues 1,158,521 786,650
------------- -------------
Total current liabilities 2,267,333 2,105,033
------------- -------------
STOCKHOLDERS' EQUITY (DEFICIT):
Convertible preferred stock, $5.00 par value, 3,000,000
shares authorized; issued-none -- --
Common stock, $.001 par value, 200,000,000 shares authorized,
112,870,031 and 109,329,098 issued and outstanding on
September 30, 2003 and June 30, 2003, respectively 112,869 109,329
Additional paid-in capital 95,194,841 94,041,104
Other comprehensive income -- --
Deficit accumulated during the development stage (95,537,725) (94,433,788)
------------- -------------
Total stockholders' equity (deficit) (230,015) (283,355)
------------- -------------
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY $ 2,037,318 $ 1,821,678
============= =============
The accompanying notes are an integral part of these
consolidated financial statements.
2
COMPUTERIZED THERMAL IMAGING, INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND OTHER COMPREHENSIVE INCOME (LOSS)
(A DEVELOPMENT STAGE COMPANY)
(UNAUDITED)
FROM
FOR THE JUNE 10, 1987
THREE MONTHS ENDED (INCEPTION)
SEPTEMBER 30, THROUGH
--------------------------------- --------------
2003 2002 30-SEP-03
-------------- -------------- --------------
INCOME:
Product revenues $ 57,189 $ 250,930 $ 3,133,677
Service revenues 5,508 13,000 349,490
-------------- -------------- --------------
Total Revenues 62,697 263,930 3,483,167
-------------- -------------- --------------
Cost of product revenues (42,402) (200,477) (2,495,394)
Cost of service revenues -- (3,900) (76,527)
-------------- -------------- --------------
Total cost of revenues (42,402) (204,377) (2,571,921)
-------------- -------------- --------------
GROSS MARGIN 20,295 59,553 911,246
-------------- -------------- --------------
OPERATING EXPENSES:
Operating, general and administrative 544,976 832,791 35,031,790
Litigation settlements -- -- 2,697,434
Research and development 366,906 1,248,312 31,122,757
Marketing 154,056 608,515 8,562,185
Depreciation and amortization 54,797 163,584 5,110,212
Impairment loss -- -- 12,322,192
-------------- -------------- --------------
Total operating expenses 1,120,735 2,853,202 94,846,570
-------------- -------------- --------------
OPERATING LOSS (1,100,440) (2,793,649) (93,935,324)
-------------- -------------- --------------
OTHER INCOME (EXPENSE):
Interest income 1,928 89,349 3,605,367
Interest expense (5,425) (717,650) (5,189,436)
Other -- -- 193,711
-------------- -------------- --------------
Total other income (expense) (3,497) (628,301) (1,390,358)
-------------- -------------- --------------
LOSS BEFORE EXTRAORDINARY ITEM (1,103,937) (3,421,950) (95,325,682)
EXTRAORDINARY GAIN ON
EXTINGUISHMENT OF DEBT -- -- 65,637
-------------- -------------- --------------
NET LOSS (1,103,937) (3,421,950) (95,260,045)
OTHER COMPREHENSIVE INCOME (LOSS)
Unrealized gain (loss) on investments available for sale -- 14,433 --
-------------- -------------- --------------
TOTAL COMPREHENSIVE (LOSS) $ (1,103,937) $ (3,407,517) $ (95,260,045)
============== ============== ==============
WEIGHTED AVERAGE SHARES
OUTSTANDING 112,344,005 83,135,384
============= =============
BASIC AND DILUTED LOSS PER COMMON SHARE $ (0.01) $ (0.04)
============= =============
The accompanying notes are an integral part of these
consolidated financial statements.
3
COMPUTERIZED THERMAL IMAGING, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS
(A DEVELOPMENT STAGE COMPANY)
(UNAUDITED)
FOR THE FROM
THREE MONTHS ENDED JUNE 10, 1987
SEPTEMBER 30, (INCEPTION)
-------------------------------- THROUGH
2003 2002 SEPTEMBER 30, 2003
------------- ------------- -------------
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $ (1,103,937) $ (3,421,950) $(95,260,045)
Adjustments to reconcile net income (loss) to net cash
used in operating activities:
Depreciation and amortization 54,797 163,584 5,110,212
Impairment loss and (gain) loss on disposition of assets (15,192) -- 12,281,604
Amortization of bond premium (discount) -- 24,316 51,447
Amortization of discount on convertible debenture
and deferred finance costs -- 388,904 1,648,594
Conversion expense of convertible debenture -- -- 1,776,839
Common stock, warrants, and options issued
as compensation for services -- -- 9,639,920
Options extended beyond their expiration date -- -- 1,687,250
Common stock issued for interest expense -- -- 423,595
Stock-based compensation on options marked to market -- 7,280 347,075
Common stock issued to settle litigation -- -- 514,380
Options issued at discount to market to settle litigation -- -- 475,000
Options issued at discount to market as
compensation expense -- -- 226,586
Common stock issued for failure to complete
timely registration -- -- 82,216
Common stock issued to 401(k) plan -- -- 117,860
Extraordinary gain on extinguishment of debt -- -- (65,637)
Bad debt expense 63,032 (30,713) 509,755
Interest expense on convertible debenture -- 287,164 492,406
Changes in operating assets and liabilities:
Accounts receivable - trade 328,352 (249,977) (98,600)
Accounts receivable - other -- 57,151 265,912
Inventories (27,846) (94,491) (156,952)
Prepaid expenses 118,268 173,068 49,794
Accounts payable (26,985) (279,087) 475,200
Accrued liabilities (28,279) 72,586 263,254
Accrued litigation settlement -- (1,300,000) 100,000
Deferred revenues 371,871 387,947 1,158,521
------------- ------------- -------------
Net cash used in operating activities (265,919) (3,814,218) (57,883,814)
------------- ------------- -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Proceeds from sale of assets 22,177 -- 153,973
Capital expenditures -- (50,387) (2,812,907)
Acquisition of Thermal Imaging, Inc. common stock -- -- (100,000)
Purchase of software license -- -- (3,850,000)
Purchase of investments available for sale -- -- (43,851,010)
Proceeds from redemption of investments available for sale -- 3,514,989 43,468,857
Acquisition of Bales Scientific common stock,
net of cash acquired -- -- (5,604,058)
------------- ------------- -------------
Net cash provided by (used in) investing activities 22,177 3,464,602 (12,595,145)
------------- ------------- -------------
The accompanying notes are an integral part of these
consolidated financial statements.
4
COMPUTERIZED THERMAL IMAGING, INC.
CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS (Continued)
(A DEVELOPMENT STAGE COMPANY)
(UNAUDITED)
FOR THE FROM
THREE MONTHS ENDED JUNE 10, 1987
SEPTEMBER 30, (INCEPTION)
------------------------------- THROUGH
2003 2002 SEPTEMBER 30, 2003
------------- ------------- -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from issuance of common stock and warrants,
net of offering costs $ 1,000,000 $ 82,069 $ 64,976,581
Advances to affiliate -- -- (107,864)
Advances from stockholders -- -- 2,320,738
Preferential Dividend -- -- (79,000)
Proceeds from issuances from covertible debentures,
net of finance costs -- -- 5,756,339
Payments on debt -- -- (1,177,190)
------------- ------------- -------------
Net cash provided by financing activities 1,000,000 82,069 71,689,604
------------- ------------- -------------
NET INCREASE (DECREASE) IN CASH
AND CASH EQUIVALENTS 756,258 (267,547) 1,210,645
CASH AND CASH EQUIVALENTS AT
BEGINNING OF PERIOD 454,387 936,796 --
------------- ------------- -------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $ 1,210,645 $ 669,249 $ 1,210,645
============= ============= =============
SUPPLEMENTAL CASH FLOW INFORMATION
Cash paid for:
Interest expense $ -- $ -- $ 8,770
Income taxes -- -- --
SUPPLEMENTAL SCHEDULE OF NON-CASH
FINANCING AND INVESTING ACTIVITIES
Common stock issued to reduce debenture, interest and
penalty $ 157,277 $ 203,064 $ 2,992,406
Warrants issued for financing costs -- -- 118,905
Common stock issued to individuals to acquire
minority interest of subsidiary -- -- 165,500
Common stock issued in consideration of Bales Scientific -- -- 5,500,000
Options issued at discount to market in connection
with offering -- -- 744,282
Stock offering costs capitalized -- -- (744,282)
Common stock issued for advances from shareholders -- -- 2,320,738
Common stock issued for notes payable, accrued
discount and interest -- -- 2,224,953
Common stock issued for convertible subordinated
debentures -- -- 640,660
Common stock issued for liabilities -- -- 50,000
The accompanying notes are an integral part of these
consolidated financial statements.
5
COMPUTERIZED THERMAL IMAGING, INC.
(A Development Stage Company)
Notes to Condensed Consolidated Financial Statements
(UNAUDITED)
NOTE A. UNAUDITED FINANCIAL STATEMENTS AND BASIS OF PRESENTATION
The condensed consolidated financial statements of Computerized Thermal
Imaging (the "Company") for the three-month periods ended September 30, 2003 and
2002 are unaudited. In the opinion of management, all adjustments (consisting of
normal recurring accruals) considered necessary for a fair presentation of the
Company's results of operation for the periods presented have been included.
These interim statements should be read in conjunction with the audited
consolidated financial statements and footnotes thereto contained in the
Company's most recent Annual Report on Form 10-K for the Year Ended June 30,
2003. The consolidated results of operations for the three-month period ended
September 30, 2003 are not necessarily indicative of the results to be expected
for the full year.
Certain amounts from the prior period financial statements have been
reclassified to conform to current period presentation.
The preparation of financial statements in conformity with accounting
principles generally accepted in the United States requires management to make
estimates and assumptions, including for example, accounts receivable
allowances, inventory obsolescence reserves, deferred tax valuation allowances,
and reserves for pending or threatened litigation. These assumptions affect the
reported amounts of assets and liabilities and disclosure of contingent assets
and liabilities at the date of the financial statements and the reported amounts
of revenues and expenses during the reporting period. Actual results could
differ from these estimates.
The accompanying condensed consolidated financial statements have been
prepared assuming the Company will continue as a going concern. In its Annual
Report on Form 10-K for the Year Ended June 30, 2003, the Company reported that
its recurring losses from operations, negative cash flows from operations,
pending shareholder class-action lawsuits and denial of coverage for any
resulting claims by the Company's provider of directors and officers insurance,
forced redemption of the Company's convertible debentures, the Company's need
for additional working capital, and the possibility that the Company may not
receive FDA approval for its primary product raised substantial doubt about the
Company's ability to continue as a going concern.
In order to pursue its existing plan of operations, the Company will
have to secure additional financing through the sale of equity, the incurrence
of debt or the sale of assets, including the Company's intellectual property.
There can be no assurance that capital will be available from any source or, if
available, that the terms and conditions associated with such capital will be
acceptable to the Company. If the Company raises equity or debt capital, the
sale of these securities could dilute existing shareholders, and borrowings from
third parties could result in assets being pledged as collateral and could
provide loan terms that could adversely affect the Company's operations and the
price of its common stock.
6
The accompanying consolidated financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might be necessary
if the Company is unable to continue as a going concern.
NOTE B. RECENTLY ISSUED ACCOUNTING STANDARDS
In October 2002, the Financial Accounting Standards Board (the "FASB")
issued Statement of Financial Accounting Standards No. 147 (SFAS 147),
ACQUISITIONS OF CERTAIN FINANCIAL INSTITUTIONS. SFAS 147 provides that the
guidance provided by SFAS 141 BUSINESS COMBINATIONS, SFAS 142 GOODWILL AND OTHER
INTANGIBLE ASSETS, and SFAS 144 ACCOUNTING FOR THE IMPAIRMENT OR DISPOSAL OF
LONG-LIVED ASSETS will apply to acquisitions of financial institutions
(previously covered under special industry guidance). The transition provisions
of SFAS 147 became effective on October 1, 2002. At this time the Company does
not believe the adoption of SFAS 147 will have any impact on its condensed
consolidated financial statements.
In December 2002, the FASB issued Statement of Financial Accounting
Standards No. 148 (SFAS 148), ACCOUNTING FOR STOCK-BASED COMPENSATION -
TRANSITION AND DISCLOSURE, which amends Statement of Financial Accounting
Standards No. 123, ACCOUNTING FOR STOCK-BASED COMPENSATION. SFAS 148 provides
alternative methods of transition for a voluntary change to the fair value
-based method of accounting for stock-based employee compensation and requires
more prominent and more frequent disclosures in the financial statements of the
effects of stock-based compensation. The provisions of SFAS 148 are effective
for fiscal years ending after December 15, 2002 and the interim disclosure
provisions are effective for interim periods beginning after December 15, 2002.
The Company began providing the required interim and annual disclosures
beginning in the quarter ended March 31, 2003.
In February 2003, the FASB issued Statement of Financial Accounting
Standards No. 149 (SFAS No. 149), ACCOUNTING FOR CERTAIN FINANCIAL INSTRUMENTS
WITH CHARACTERISTICS OF LIABILITIES AND EQUITY, which became effective at the
beginning of the first interim period beginning after March 15, 2003. SFAS No.
149 establishes standards for the Company's classification of liabilities in the
financial statements that have characteristics of both liabilities and equity.
The Company does not believe the adoption of SFAS No. 149 will have a material
effect on the Company's consolidated financial position or results of
operations.
In May 2003, the FASB issued Statement of Financial Accounting
Standards No. 150 (SFAS No. 150) ACCOUNTING FOR CERTAIN FINANCIAL INSTRUMENTS
WITH CHARACTERISTICS OF BOTH LIABILITIES AND EQUITY, which is effective the
first interim period beginning after June 15, 2003. SFAS No. 150 establishes
standards for how the Company classifies and measures in its statement of
financial position certain financial instruments with characteristics of both
liabilities and equity. The Company does not believe the adoption of SFAS No.
150 will have a material effect on the Company's consolidated financial position
or results of operations.
7
NOTE C. CONVERTIBLE DEBENTURE
Financing Agreement with Beach Boulevard, LLC.
On December 31, 2001, the Company entered into a financing agreement
(the "Beach Boulevard Agreement") with Beach Boulevard, LLC (the "Investor"),
pursuant to which the Company issued a 7% convertible debenture in the amount of
$2.5 million (the "Debenture Offering") and obtained an equity line of credit
(the "Equity Line") that enabled the Company to sell up to $20 million in common
stock to the Investor at 94% of the market price, as defined by the Beach
Boulevard Agreement. The convertible debenture was originally due on December
31, 2004. The terms of the Beach Boulevard Agreement permit the Investor to
convert the convertible debenture into 2,100,694 shares of common stock at a
conversion price of $1.44 per share at any time during the term of the Beach
Boulevard Agreement. Interest on the convertible debenture is due on the
conversion date and is payable, in cash or common stock.
In connection with the Beach Boulevard Agreement, the Company entered
into a registration rights agreement and subsequently filed with the Securities
and Exchange Commission (the "Commission") a Registration Statement on Form S-3,
which was declared effective on March 18, 2002 (Registration No. 333-82016).
Prior to completing the transactions contemplated by the Beach Boulevard
Agreement, the Company terminated its 1999 agreement with Beach Boulevard to
purchase up to $7 million of its common stock.
As of September 30 2003, Company had satisfied all of its obligations
set forth in the Beach Boulevard Agreement. Over the life of the Beach Boulevard
Agreement a total of 26,487,821 shares of common stock were issued to the
Investor. Of those shares, 20,462,816 shares were issued to retire the
debenture, 3,764,321 shares were issued in connection with the equity line,
260,417 shares were issued upon the exercise of warrants, and 2,026,074 shares
were issued to satisfy interest and penalty obligations. The Company incurred
approximately $438,696 to obtain proceeds of $3,457,956 from the debenture and
equity line of credit. On July 7, 2003, the Company issued 196,451 shares of
common stock to the Investor, in order to satisfy $157,277 of interest and
penalty and to terminate the Beach Boulevard Agreement.
In order to pursue its existing plan of operations, the Company will
have to secure additional financing through the sale of equity, the incurrence
of debt or the sale of assets, including the Company's intellectual property.
There can be no assurance that capital will be available from any source or, if
available, that the terms and conditions associated with such capital will be
acceptable to the Company. If the Company raises equity or debt capital, the
sale of these securities could dilute existing shareholders, and borrowings from
third parties could result in assets being pledged as collateral and could
provide loan terms that could adversely affect the Company's operations and the
price of the Company's common stock.
8
The accompanying consolidated financial statements do not include any
adjustments relating to the recoverability and classification of recorded asset
amounts or the amounts and classification of liabilities that might be necessary
if the Company is unable to continue as a going concern.
NOTE D. REVENUE RECOGNITION
The Company generates revenues from sales of its products and from
services provided to its customers. The Company sells its products to
independent distributors and to end customers. With the exception of sales
transactions in which a customer may return defective product, the Company does
not provide its customers with other rights to return products.
The Company recognizes revenue from its product sales to end customers
upon shipment of products when persuasive evidence of an agreement exists,
delivery of the product has occurred, no significant Company obligations remain,
the fee is fixed or determinable, and collectibility is probable. If these
conditions are not met, revenue is deferred until such obligations and
conditions are fulfilled. If the Company retains an ongoing obligation under a
sales arrangement, revenue is deferred until all of the Company's obligations
are fulfilled.
Effective July 1, 2001, the Company adopted the practice of deferring
revenue on shipments to distributors until cash payment from the distributor is
received by the Company, which is generally when the product is sold by the
distributor to the end customer. Prior to that date, revenue on shipments to
distributors was recognized upon shipment to the distributor if all of the
criteria for revenue recognition were satisfied. The Company believes that
deferral of revenue on shipments to distributors until cash payment is received
is a more meaningful measurement of results of operations.
Certain of the Company's products contain software that is not
considered incidental to the product. Sales of those products are subject to the
provisions of AICPA Statement of Position No. 97-2, SOFTWARE REVENUE
RECOGNITION, as amended, which requires the deferral of revenue from certain
multiple-element arrangements. The Company defers revenue from multiple-element
arrangements until all elements have been delivered.
Service revenue is derived from non-destructive testing of turbine
blades and other items. Service revenue is recognized upon the completion of the
services provided. The Company offers extended warranties on certain of its
products. Warranty revenue is recognized ratably over the period of the
agreement as services are provided.
9
NOTE E. DEFERRED REVENUE
Deferred revenues at September 30, 2003 was approximately $1,158,000,
and consisted of $25,000 of deferred medical revenues, $660,000 of deferred
revenues from the Nanda licensing and manufacturing agreement, $24,000 of
deferred warranty revenues and $449,000 of deferred industrial revenues and
deposits relating the Turbine Blade Inspection System ("TBIS") the Company
shipped to Pratt & Whitney. Deferred revenues at June 30, 2003 was approximately
$787,000, and consisted of $10,000 of deferred medical revenues, $300,000 of
deferred revenues associated with a manufacturing/licensing agreement (the
"Nanda Agreement") executed between the Company and NanDa Thermal Medical
Technology, Inc. ("Nanda"), $28,000 of deferred warranty revenues and $449,000
of deferred industrial revenues and deposits relating the Turbine Blade
Inspection System ("TBIS") the Company shipped to Pratt & Whitney.
DEFERRED REVENUES SEPTEMBER 30, JUNE 30,
2003 2003
Medical Products $ 25,000 $ 10,000
Nanda Licensing 660,000 300,000
Industrial Products 449,000 449,000
Warranty Revenue 24,000 28,000
----------- -----------
Total Deferred Revenue $1,158,000 $ 787,000
=========== ===========
Medical product deferred revenue consists of Thermal Image Processor
("TIP") and Photonic Stimulator ("PS") units sold to various customers and will
be recognized into revenue when outstanding obligations are compete and the
sales prices are considered fixed and determinable.
Industrial products deferred revenue consists of non-destructive
testing devices shipped to Pratt & Whitney. The Company will recognize these
sales when it has completed its obligations under the purchase agreements with
Pratt & Whitney.
The Nanda Agreement is billed in stages. Upon the execution of the
Nanda Agreement in June 2003, the Company billed Nanda $300,000; however, the
amount of the initial billing remained unpaid as of June 30, 2003 and was
collected in the quarter ended September 30, 2003. In addition, the Company
billed and collected an additional $360,000 under the Nanda Agreement during the
quarter ended September 30, 2003. The Nanda Agreement obligates the Company to
provide training services in the United States and in China. The Company will
not recognize any revenue from the Nanda Agreement until its obligations are
performed and the Company has completed its training in the U.S. and China.
NOTE F. INVENTORIES
Inventories are stated at the lower-of-cost or market with cost
determined using the first-in first-out method of accounting. As of the dates
set forth below, the Company's inventories consisted of the following:
10
SEPTEMBER 30, JUNE 30,
2003 2003
Raw materials $ 679,255 $ 673,833
Inventory Reserve $(594,674) $(594,674)
Work-in process 80,665 19,286
Finished goods 168,465 207,419
---------- ----------
Total $ 333,710 $ 305,864
========== ==========
Finished goods inventory at September 30, 2003 consisted of
approximately $168,000 of finished goods ready for sale, $80,000 in the
manufacturing process and $679,000 of raw materials. In their report on the
Company's condensed consolidated financial statements for the year ended June
30, 2003, the Company's auditors expressed concern regarding the Company's
ability to continue its operations as a going concern. As a result of that
concern, coupled with FDA's decision to not approve the BCS 2100, the Company
has treated its inventories as impaired assets on its condensed consolidated
financial statements for the quarter ended September 30, 2003. The impairment is
held in a reserve account and represents about 64% of all inventories.
The Company reserves for excess and obsolete inventory by comparing
inventory on hand to estimated consumption during the next twelve months.
Consumption is estimated by annualizing trailing three or six -month sales
volumes, adjusting those volumes for known activities and trends, then comparing
forecast consumption to quantity on hand. Any difference between inventory on
hand and greater than estimated consumption is recorded to cost of revenues and
an excess and obsolete reserve, which is included as an element of net inventory
reported on the Company's condensed consolidated balance sheet. Amounts charged
to the inventory reserves are not reversed to income until the reserved
inventory is sold or otherwise disposed. The Company felt no need to impair
additional inventory in the quarter ended September 30, 2003
NOTE G. INCOME TAXES
The Company accounts for income taxes using the liability method. Under
this method, the Company records deferred income taxes to reflect future year
tax consequences of temporary differences between the tax basis of assets and
liabilities and their financial statement amounts. The Company has reviewed its
net deferred tax assets, together with net operating loss carry-forwards, and
has provided a valuation allowance to reduce its net deferred tax assets to
their net realizable value.
11
NOTE H. CONTINGENCIES
AL-HASAWI LITIGATION --The Company is involved in a lawsuit, Al-Hasawi
v CTI, brought by Salah Al-Hasawi against the Company and its former
chief executive officer in the U.S. District Court for the Southern
District of New York in March 2000. The plaintiff alleges that the
Company failed to pay fees and grant options earned by the plaintiff in
connection with his efforts in facilitating a private placement of the
Company's securities. The plaintiff has asserted that the Company
failed to pay him commissions of approximately $516,000 plus stock
options to purchase 1,070,000 shares of common stock, valued by the
plaintiff at $15 million.
The Company has denied all of the plaintiff's claims and has
affirmatively alleged that all amounts due have been paid in full. The
Company is currently engaged in discovery and an initial hearing has
been scheduled for December 8, 2003. The likelihood of an unfavorable
outcome or the extent of any potential loss is not presently
determinable.
CLASS ACTIONS -- In 2002, five different class-action lawsuits, which
were ultimately consolidated into a single action, were filed against
the Company in the U.S. District Court in Oregon. Each suit makes
substantially the same allegations: the Company misled its shareholders
regarding such things as FDA approval and other matters, which the
plaintiffs believe caused significant damage to the Company's
shareholders at the time of these alleged misrepresentations and
omissions. The Company believes the allegations are without merit and
intends to defend them vigorously. Defending this lawsuit will require
additional legal expenses to defend, may adversely impair the Company's
ability to raise funds from outside third parties and will distract
certain members of management from day-to-day operations. Moreover, the
Company's insurance carrier has previously denied coverage of the
plaintiffs' claims and, accordingly, has indicated it will not cover
the costs of defending the claims and will not pay any resulting
damages the Company may suffer if the plaintiffs are successful.
On April 17, 2003, the consolidated class action lawsuit was dismissed
without prejudice pending repleading within 21 days by the plaintiffs
of certain allegations. The plaintiffs did not replead, and the court
issued an order of dismissal with prejudice on May 13, 2003. The
plaintiffs filed notice of appeal on May 20, 2003. The likelihood of an
unfavorable outcome or the extent of any potential loss is not
presently determinable.
SEC INVESTIGATION -- In December 2002, the Company was requested to
provide certain documents to the Commission and the U.S. Department of
Justice in connection with an investigation regarding possible
violations of the insider trading prohibitions found in the federal
securities laws. The Company has responded to the Commission's requests
for copies of documentation, and members of the Company's management
have provided testimony to the Commission. The Company's efforts to
respond to the Commission's requests has required, and in the future
may require, significant additional legal expenses, may make fund
raising more difficult if not impossible and will distract management
from day-to-day operations.
12
ST. PAUL PROPERTIES -- On April 11, 2003, St. Paul Properties, Inc.
(the "Landlord") filed suit against us in the Circuit Court for
Clackamas County. The Landlord alleges that we have breached our prior
corporate office lease by failing to pay the rent specified under the
lease. The Landlord seeks damages of approximately $667,000 plus
interest and attorneys and other fees. The Company has filed an answer
and affirmative defenses alleging that St. Paul Properties failed to
use reasonable efforts to mitigate its damages. In addition, we are
aware that much of the vacant space has been relet to a third party
tenant, substantially reducing the damage claim. The Company has
offered the sum of $40,000 to settle the matter. That offer was
rejected by the landlord, with no counter offer made by the landlord.
The Company intends to continue efforts to settle the matter.
INDEMNIFICATION -- Under the Company's bylaws and contractual
agreements the Company may be required to indemnify its current and
former officers and directors who are parties to litigation or other
proceedings by providing legal defense through the Company's attorneys
(or reimbursing the parties for their own attorneys) and covering all
damages the parties may suffer if the plaintiffs are successful.
The Company is involved in certain other litigation matters in the
normal course of business which management currently believes are not
likely to result in any material adverse effects on the financial
position, results of operations, or net cash flows of the Company.
NOTE I. FDA DEVELOPMENTS
The Company's medical imaging and treatment products are subject to
regulation by the U.S. Food and Drug Administration ("FDA"). Over the past few
years, the Company has sought approval for its Breast Cancer System through the
FDA's Pre-Market Approval process ("PMA"), which requires rigorous clinical
efficacy testing, manufacturing and other data. The Company utilized the FDA's
modular submission method and submitted its application for approval on five
modules for review.
On December 10, 2002, the Company presented the Breast Cancer System
2100(TM) ("BCS") to the FDA's Radiological Devices Panel ("Panel"), which
recommended by a vote of 4 to 3 against recommending approval of the BCS to the
FDA. On January 23, 2003, the FDA sent the Company a letter concurring with the
panel's recommendation. The letter provided specific actions the Company could
take in an effort to obtain FDA approval in the future including: (a) performing
a new pre-market clinical study, (b) modifying the indication for use, (c)
performing a reproducibility study to take into account variations encountered
in clinical practice, and (d) providing a validated daily quality assurance
procedure.
The main issues cited by the FDA were 1) the proposed indications for
use were revised on the basis of a retrospective analysis of the results in the
original PMA, 2) the additional clinical data in the "post-PMA" ("PPMA") are
insufficient by themselves to constitute an adequate study, 3) enrollment was
not limited to mammographically visible masses, and 4) the number of exclusions
of enrolled subjects was excessive.
13
Representatives of the Company met with the FDA Deputy Commissioner and
the FDA Chief Counsel on July 9, 2003. The Company was asked to provide to the
Commissioner's staff a scientific document addressing the FDA's reasons for
non-approval of the Company's application. The scientific document was sent on
July 29, 2003, and the Company is currently waiting for a response from the FDA.
Note M - Other Regulatory Matters
The Company's TIP camera is a thermal imaging device that reads
temperature (such as an external thermometer) and is completely noninvasive. In
connection with SARS screening Canada and China have used the camera's in
-airport terminals as a first line defense measure for identifying travelers
with elevated facial temperatures. Due to the noninvasive and non -SARS
diagnostic nature of the camera, both Canada and China have required minimal
governmental regulation. Before shipment of the TIP cameras, all regulatory
matters were met according to the Canadian and Chinese governments.
Note N - Segments
The Company's operations have historically been reported in two
segments: medical products and industrial products. Results of the Company's
operations for the two segments during the three-month period ended September
30, 2003 are as follows:
Medical Industrial Total
------- ---------- -----
Revenues $ 51,791 $ 10,906 $ 62,697
Cost of goods sold ( 39,130) (3,272) ( 42,402)
------------ ------------ ------------
Gross margin 12,661 7,634 20,295
Operation,general & admin. 544,976 0 544,976
Research and development 366,906 0 366,906
Marketing 154,056 0 154,056
Depreciation and amort. 54,797 0 54,797
------------ ------------ ------------
Total operating expense 1,120,735 0 1,120,735
------------ ------------ ------------
Operating loss $(1,107,974) $ 7,634 $(1,100,440)
============ ============ ============
Segment results for the three month period ended September 30, 2002
Medical Industrial Total
------- ---------- -----
Revenues $ 250,930 $ 13,000 $ 263,930
Cost of goods sold (200,477) (3,900) (204,377)
------------ ------------ ------------
Gross margin 50,453 9,100 59,553
Operation,general & admin. 674,561 158,230 832,791
Research and development 1,022,475 225,837 1,248,312
Marketing 492,897 115,618 608,515
Depreciation and amort. 146,889 16,695 163,584
------------ ------------ ------------
Total operating expense 2,336,822 516,380 2,853,202
------------ ------------ ------------
Operating loss $(2,286,369) $ (507,280) $(2,793,649)
============ ============ ============
14
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
GENERAL
Computerized Thermal Imaging, Inc. ("we", "us", "CTI" or the "Company")
designs, manufactures and markets thermal imaging devices and services used for
clinical diagnosis, pain management and industrial testing. We market our
products through an internal sales force and a network of independent
distributors.
We have developed thermal imaging technology and equipment and methods
for applying our proprietary technology. We believe our thermal imaging systems
generate data, difficult to obtain or not available using other imaging methods,
which is useful to health care providers in the detection of certain diseases
and disorders and useful to the industry for product quality testing.
Our research indicates that our equipment and technology is useful in
studying and diagnosing breast cancer, which is the second most common cancer in
women. Our research and development efforts led to the creation of our breast
imaging system, known as the "BCS 2100." We are seeking FDA pre-market approval
for the BCS 2100 as an adjunct to mammography and clinical examinations for use
as a painless and non-invasive technique for acquiring clinical information. To
receive pre-market approval ("PMA") from the FDA, we must establish the BCS
2100's ability to consistently distinguish between malignant and benign tissue
and thereby reduce the number of breast biopsies performed on benign tissue. We
have received acceptance on four of the five modules required for PMA approval.
We submitted the fifth module, which includes clinical trial results and
efficacy claims, during June 2001.
We presented the BCS 2100 to the FDA's Radiological Devices Panel on
December 10, 2002 and the Panel voted against approval of the BCS 2100. On
January 23, 2003, the FDA concurred with the recommendation made by the Panel
and issued to the Company a non-approval letter with respect to the BCS 2100. We
believe the FDA's decision was based on technical and statistical issues
regarding the clinical trial and analysis of the clinical trial data. The main
issues cited by the FDA were 1) the proposed indications for use were revised on
the basis of a retrospective analysis of the results in the original PMA, 2) the
additional "post-PMA" clinical data are insufficient to constitute an adequate
study, 3) enrollment was not limited to mammographically visible masses, and 4)
the number of exclusions of enrolled subjects was excessive. The FDA's letter
states specific actions we could take in an effort to put the PMA into an
approvable form including: a) performing a new pre-market clinical study, (b)
modifying the indication for use, (c) performing a reproducibility study to take
into account variations encountered in clinical practice, and (d) providing a
validated daily quality assurance procedure.
15
Our management met with the FDA Deputy Commissioner and the FDA Chief
Counsel on July 9, 2003. We were asked to provide to the Deputy Commission's
staff a scientific document addressing the FDA's reasons for non-approval. The
scientific document was sent on July 29, 2003, and we are currently waiting for
a response.
Our common stock is publicly traded on the American Stock Exchange
under the symbol "CIO". On October 30, 2003, we had approximately 113 million
shares of common stock outstanding held by approximately 21,000 shareholders. In
addition to shares of common stock outstanding, as of October 30, 2003, we had
approximately 4.5 million shares of common stock underlying warrants and options
that remain unexercised. On a fully diluted basis, we have approximately 117.5
million shares of common stock outstanding, approximately 19% of which are
beneficially owned by insiders and affiliates. We currently have no other
interest in any other entity.
We use capital to pay general corporate expenses, including salaries,
manufacturing costs, professional fees, clinical trials, technical support costs
and general and administrative expenses. To date, we have funded our business
activities with funds raised through the private placement of common stock, debt
and warrants and the exercise of warrants and options.
This Report contains forward-looking statements within the meaning of
the Securities Act of 1933, as amended, and Securities Exchange Act of 1934, as
amended. Forward-looking statements involve known and unknown risks,
uncertainties and other factors which may cause our actual results, performance
or achievements to be materially different from any expected results,
performance or achievements. When used in this document the words "expects",
"anticipates," "intends," "plans," "may," "believes," "seeks," "estimates," and
similar expressions generally identify forward-looking statements. All
forward-looking statements included in this Report are based on information
available to us on the date hereof, and we assume no obligation to update any
forward-looking statements except to the extent required under applicable
securities laws.
The following discussion and analysis of our consolidated financial
condition and results of operations should be read in conjunction with our
audited condensed consolidated financial statements and notes thereto contained
in our Annual Report on Form 10-K for the fiscal year ended June 30, 2003.
16
CRITICAL ACCOUNTING POLICIES
The preparation of financial statements and related disclosure in
conformity with accounting principles generally accepted in the United States of
America and our discussion and analysis of our financial condition and results
of operation requires management to make estimates and assumptions that affect
the reported amounts of assets and liabilities, the disclosure of contingent
assets and liabilities at the date of the financial statements and the reported
amounts of revenues and expenses during the reporting period. Actual results
could differ from those estimates.
We believe the following are our critical accounting policies. That is,
they are both important to the portrayal of our financial condition and results,
and they require management to make judgments and estimates about matters that
are inherently uncertain.
CASH AND CASH EQUIVALENTS-- Cash and cash equivalents include cash in
checking accounts and short-term highly liquid investments with an original
maturity of one year or less.
REVENUE RECOGNITION -- Although we believe revenues recognized to date
have been immaterial to our financial statements, we also believe revenue
recognition is a significant business process that requires management to make
estimates and assumptions. We recognize revenue from product sales after
shipment when persuasive evidence of an agreement exists, delivery of the
product has occurred, no significant obligations remain, the price or fee is
fixed or determinable, and collection is probable. If these conditions are not
met, revenue is deferred until such obligations and conditions are fulfilled.
Our standard domestic terms for our medical products to end-user
customers are "net 30 days," and our standard international terms for our
medical products require payment in cash or placement of a letter of credit
before shipment. On occasion, we offer extended payment terms beyond our normal
business practices, usually in connection with providing an initial order of
demonstration equipment to a new domestic distributor. We consider fees on these
extended terms agreements not fixed and collectibility less than probable and
defer the revenue until receipt of payment. Our sales prices have declined over
time and we credit price decreases to any balance due from a distributor. We
sell separate extended warranty contracts for our Thermal Image Processor
("TIP") and Photonic Stimulator and recognize revenue from those arrangements
ratably over the contract life. We do not offer rights or return privileges in
sales agreements.
Industrial sales are made pursuant to individually negotiated
commercial contracts which specify payment terms that have ranged from 60 to 90
days from shipment or service completion. With industrial products, even if
delivery and payment have occurred, we may retain a significant ongoing
obligation under a sales arrangement for the delivery of components or
customized software and customer testing, and we defer recognizing revenue until
all the multiple elements of the sale are completed.
17
RESEARCH AND DEVELOPMENT EXPENSES -- We expense as incurred the direct,
indirect and purchased research and development costs associated with our
products. We believe this method is conservative given the product and market
acceptance risk inherent to our products and reduces administrative burden and
cost.
IMPAIRMENT OF LONG-LIVED ASSETS -- We follow the provisions of
Financial Accounting Standards Board ("FASB") SFAS No. 141, ACCOUNTING FOR THE
IMPAIRMENT OF LONG-LIVED ASSETS AND FOR LONG-LIVED ASSETS TO BE DISPOSED OF,
which requires that if the sum of the future cash flows expected to result from
the assets, undiscounted and without interest charges, is less than a company's
reported value of the assets, the asset is not recoverable and the company must
recognize an impairment. The amount of impairment to be recognized is the excess
of the reported value of the assets over the fair value of those assets and is
recorded as impairment expense on our statements of operations. In estimating
impairments, management makes assumptions about future cash flows and fair value
that are inherently uncertain, can significantly affect the results and may
differ from actual future results.
INVENTORY RESERVES -- We establish reserves for excess and obsolete
inventory by comparing inventory on hand to estimated consumption during the
subsequent twelve-month period. Consumption is estimated by annualizing trailing
three or six -month sales volumes, adjusting those volumes for known activities
and trends, and comparing forecast consumption to quantity on hand. Any
difference between inventory greater than estimated consumption is recorded to
cost of revenues and an excess and obsolete reserve, which is included as an
element of net inventory reported on our Balance Sheet. Amounts charged to the
inventory reserves are not reversed to income until the reserved inventory is
sold or otherwise disposed.
EMPLOYEE INCENTIVE PLANS -- Pursuant to employment agreements and
verbal commitments, we provide to certain employees incentive compensation
ranging from five percent to ten percent of their annual salary. We have
terminated our discretionary 401(k) plan. All CTI common stock formerly held in
our 401(k) plan was sold and the proceeds were placed in funds as selected by
each individual employee. We are in the process of issuing lump sum
distributions and qualified plan rollovers for each participant. We expect to
complete the process by December 31, 2003.
TRENDS/UNCERTAINTIES AFFECTING CONTINUING OPERATIONS
We are exposed to the opportunities and risks usually associated with
marketing and manufacturing novel products, including staff retention and
recruiting, market acceptance of our products, product warranty, bad debts and
inventory obsolescence. We expect to earn revenues from the sale of our
products, but there is no guarantee that these revenues will recover all the
costs of marketing, selling and manufacturing our products.
Our marketing efforts rely upon building relationships with
manufacturers, medical equipment dealers, physicians and clinical investigators.
We communicate with our target markets by attending trade shows and conferences,
making direct sales calls, and sponsoring clinics where we introduce and
demonstrate our products. We believe marketing medical products through trade
shows, conference presentations, direct mail and inside sales augmented with
18
dealers provides a low-cost, high-leverage approach to diagnostic imaging and
pain management practitioners. To the extent possible, we plan to continue
investing resources in these programs, although there can be no assurance they
will lead to market acceptance of our products.
We organize clinical studies with institutions and practitioners to
obtain user feedback and to secure technical papers for training and marketing
purposes. These strategies represent a significant investment of time and
resources and have provided useful information; however, there can be no
guarantee that these strategies will lead to market acceptance of our products.
To date, we have had limited operating revenues from the sale of our
products and services ($3.5 million in total revenues since inception). We
cannot provide any assurance that we will achieve profitability in the future.
Our immediate priorities are to reconcile issues presented to us by the FDA
Advisory Panel on December 10, 2002 and FDA administrators in subsequent
meetings, and the pursuit of additional funding. At this time, we are unsure how
much time and additional financing we will require to resolve these issues with
the FDA. We are also unsure about our ability to raise additional financing that
will be required to continue our business operations. These uncertainties, among
others, raise doubts about our ability to continue as a going concern.
FACTORS THAT MAY AFFECT FUTURE RESULTS
Our operating results and financial condition are subject to
substantial risks and uncertainties. These risks and uncertainties include, but
are not limited to, the following:
Our failure to raise additional capital could cause us to severely
curtail operations, which would adversely affect shareholder value, or cease
operations entirely, which would likely eliminate any value in our common stock.
Our failure to obtain FDA approval of our BCS 2100 would have a
material adverse impact on our results of operation and financial condition, and
may result in cessation of our operations entirely.
We are involved in substantial shareholder litigation, which may have
an adverse impact on us and our shareholders.
We have limited revenues from operations and may never have substantial
revenue from operations.
Failure to obtain insurance reimbursement codes for our BCS 2100 may
make the BCS 2100 unmarketable, thereby adversely affecting shareholder value.
19
We expect to continue to incur losses, deficits, and deficiencies in
liquidity for the foreseeable future. Unless we are able to reverse those
trends, we will likely be unable to continue our operations.
We may sell assets or reduce activities to fund operations, which could
adversely affect shareholder value.
The recent volatility in the market price of our common stock could
continue and adversely affect shareholder value.
We could issue preferred stock or sell other securities or other
financing instruments, including convertible debt, which could result in
significant dilution to existing shareholders.
We rely on third parties in the development and manufacture of key
components for our products. If they fail to perform, product development,
and/or production could be substantially delayed.
If we are unsuccessful in preventing others from using our intellectual
property, we could lose a competitive advantage.
We do not have product liability insurance; if we are made subject to a
products liability claim, whether or not the claim is meritorious, our results
of operation and financial condition may be adversely affected.
We do not currently meet the requirements for continued listing on the
American Stock Exchange. In particular, we do not currently maintain the
required level of shareholder equity, we have incurred operating losses for two
of the past three years, and our financial condition is impaired. If these
conditions are not rectified, our common stock will likely be delisted from the
American Stock Exchange. If our common stock is delisted, there may be no
trading market for our common stock.
OTHER FACTORS THAT MAY AFFECT FUTURE RESULTS.
The foregoing factors should be read in conjunction with our audited
consolidated financial statements, notes thereto and risk factors set forth in
our Annual Report on Form 10-K for the fiscal year ended June 30, 2003 (the
"Form 10-K"). Many of the risks identified above are discussed in greater detail
in the Form 10-K.
20
RESULTS OF OPERATIONS
QUARTER ENDED SEPTEMBER 30, 2003, COMPARED TO QUARTER ENDED SEPTEMBER 30, 2002.
REVENUES
Revenues for the quarter ended September 30, 2003 decreased $201
thousand, or 76%, from the same period last year to $63 thousand; $52 thousand
of our revenues resulted from the sale of pain management products; the
remaining $11 thousand was warranty and industrial services. The decrease was
due to a decrease in pain management products sales that partly can be
attributed to the reduction in sales force.
During the quarter ended September 30, 2003, medical segment revenues
were $51 thousand, compared to $251 thousand from the same period last year,
resulting in an decrease of $200 thousand, or 80%. This decrease resulted
primarily from the absence of foreign sales and decreased sales activity
overall. The primary source of the decline was associated with the TIP camera.
We did not sell any TIP systems in the quarter ended September 30, 2003,
compared to TIP sales during the same period last year of $168 thousand. In the
quarter ended September 30, 2002 there were 5 cameras sold, two of which were
sold to NanDa Thermal Medical Technology, Inc. ("Nanda") for use in China. The
sale of Photonic Stimulator units decreased approximately 41% in the quarter
ended September 30, 2003 compared to the same period of 2002.
During the quarter ended September 30, 2003, industrial segment
revenues were $11 thousand, compared to $13 thousand for the same period last
year, resulting in an decrease of $2 thousand. No industrial units were sold in
either quarter. The industrial revenue was limited to service on previously sold
units.
During the quarter ended September 30, 2003, no overhead expenses were
allocated to the industrial segment of our operations, due to our reduction in
sales staff and decreased development in the segment.
There were no unfulfilled orders as of September 30, 2003; as of
September 2002 there was $425 thousand in unfilled orders. Backlog at September
30, 2002 was an order from Pratt & Whitney for a Turbine Blade Inspection System
("TBIS"). This order was shipped during fiscal 2003 and will be recognized as
revenue when all of our commitments and obligations associated with the order
have been fulfilled. Although the Pratt & Whitney revenue has not yet been
recognized on our financial statements, it is not considered "backlog" because
the unit has been shipped but is still waiting final customer acceptance.
We recognized $18 thousand, or 29% of total revenue, in foreign sales
during the quarter ended September 30, 2003, compared to approximately $239
thousand, or 40% of total revenues, for the quarter ended September 30, 2002.
Revenues during the quarter ended September 30, 2003 were attributable to the
rental of camera to a Canadian entity. Sales during the comparable quarter of
2002 consisted of $187 thousand in medical sales, primarily to Canada and China,
and $52 thousand in industrial sales to the United Kingdom.
21
COSTS AND EXPENSES
Gross margins for the quarter ended September 30, 2003 were $20
thousand, compared to $60 thousand for the same period last year. Total cost of
goods sold for the quarter ended September 30, 2003 were approximately $42
thousand, compared to $204 thousand for the same period last year.
We expect that unit prices for our TIP System and Photonic Stimulator
will continue to decline as a prerequisite to increasing market penetration. We
also expect prices to decline faster than we will be able to reduce
manufacturing costs; therefore, we anticipate our gross margins as a percentage
of sales for our pain management products will decline. Demand for our pain
management products and resulting revenues and gross margins are dependant upon
general economic conditions, insurance reimbursements, insurance coverage
offered by medical plans and our ability to aggressively market and promote our
products.
General and administrative expenses for the quarter ended September 30,
2003 were $545 thousand, compared to $833 thousand for the same period last
year, a decrease of $288 thousand, or 35%. The decrease reflects our effort to
reduce costs and preserve cash. The decrease reflected declines in salary
expense ($229 thousand), office expense ($66 thousand), and professional
services expense ($25 thousand), offset by an increase in legal fees of $32
thousand.
Research and development expenses for the quarter ended September 30,
2003 were $367 thousand, compared to $1,248 thousand for the same period last
year, a decrease of $881 thousand, or 71%. The reduction in research and
development expense reflects our efforts to preserve cash. Reductions in salary
expense accounted for $602 thousand of the decrease, decreased medical R&D
resulted in a decrease of $62 thousand, and decreases in rent ($75 thousand),
regulatory expenses ($45 thousand), insurance ($30 thousand) and outside
services, travel and misc. ($109 thousand) offset by increases in legal expenses
of $42 thousand, also reduced our research and development expense.
Marketing expenses for the quarter ended September 30, 2003 were $154
thousand, compared to $609 thousand for the same period last year, a decrease of
$455 thousand, or 75%, from the same period of last year. Reduction in salaries
accounted for $256 thousand of the decrease, marketing and advertising expenses
declined by $129 thousand, we reduced travel by $35 thousand, we reduced office
rent by $28 thousand, and we reduced Insurance expense by $20 thousand. The
decrease reflected management's efforts to preserve our cash position.
We believe securing a favorable recommendation from the FDA is critical
to obtaining additional funding. However, due to the delay in FDA response, we
have been forced to conserve cash by reducing expenses throughout the company.
We feel it is not wise to continue development of a product that has not yet
been approved by the FDA.
We plan to continue conducting clinical studies at a much reduced
level, utilizing the BCS 2100, with institutions and practitioners to obtain
user feedback, test product enhancements as they become available, to secure
technical papers and for training and educational marketing purposes. Clinical
studies are not the same as clinical trials, which we conducted for FDA PMA
approval purposes.
22
Depreciation and amortization expense for the quarter ended September
30, 2003 decreased $92 thousand to $55 thousand, or 63%, compared to the prior
year period. During fiscal 2003, we impaired all assets to reflect possible
recovery values due to the concern expressed by our auditors that CTI may not be
able to continue as a going concern. There was no additional impairment in the
quarter ended September 30, 2003.
OPERATING INCOME / LOSS
Principally as a result of the foregoing, we recorded an operating loss
of $1.1 million for the quarter ended September 30, 2003, compared to an
operating loss of $2.8 million for the quarter ended September 30, 2002. Sales
in the medical segment accounted for most of our revenue in the quarter ended
September 30, 2003. Our activities in the industrial segment during the quarter
resulted primarily in service revenues with some labor costs.
OTHER INCOME
Net interest expense for the quarter ended September 30, 2003 decreased
$625 thousand from the same quarter of 2002, to a net expense of $3 thousand.
This decrease resulted primarily from the retirement of the Convertible
Debenture described below. See Item 3. Defaults Upon Senior Securities.
NET INCOME/(LOSS)
We recorded a net loss of $1.1 million for the quarter ended September
30, 2003, compared to a net loss of 3.4 million for the quarter ended September
30, 2002. For the quarter ended September 30, 2003, the loss attributable to
common shareholders was $1.1 million, or ($0.01) per share, compared to a loss
attributable to common shareholders of $3.4 million, or ($0.04) per share, for
the quarter ended September 30, 2002.
LIQUIDITY AND CAPITAL RESOURCES
SOURCES AND USES OF LIQUIDITY
Our sources of funds used for operations have historically come from
selling common stock, as well as the issuance and exercise of options and
warrants, revenues generated from operations, sales of marketable securities,
interest earned from marketable securities available for sale and debt
assumption.
Our cash requirements include, but are not limited to, general
corporate expenses including employee salaries and benefits, lease payments on
office space, legal and accounting fees for litigation and to comply with
securities registration and reporting requirements, costs of clinical trials and
studies and technical support, FDA consulting expenses, procurement of inventory
and supply expenses associated with our efforts to develop, manufacture and
market our medical and industrial applications. We have reduced many of these
costs in an effort to preserve cash; however, a significant amount of these
costs are attributable to activities that are necessary to continue our
operations.
23
Net cash used in operating activities for the three months ended
September 30, 2003 was $266 thousand, compared to $3,814 thousand for the three
months ended September 30, 2002. The decrease in cash used in operating
activities was primarily a result of our efforts to decrease our expenses and
cash outlays and is affected by fluctuations in accounts receivable, accounts
payable and accrued expense balances.
Excluding an allowance for doubtful accounts of $66 thousand for the
three months ended September 30, 2003, accounts receivable decreased
approximately $328 thousand from $423 thousand to $95 thousand at September 30,
2003 compared to June 30, 2003. This decrease in receivables primarily relates
to one invoice to Nanda for $300 thousand related to a prepayment required by
the contract. We have deferred our recognition of revenue under the Nanda
agreement until we have satisfied our obligations under the agreement.
Net cash provided by investing activities for the three months ended
September 30, 2003 was $22 thousand, compared to net cash used in investing
activities of $3,465 thousand in the three months ended September 30, 2002. Net
cash provided by and used in investing activities was provided by the sale of
fixed assets in connection with our office consolidation process for fiscal
2003, whereas net cash in 2002 was from the sale of securities.
Net cash provided by financing activities was $1,000 thousand for the
three months ended September 30, 2003, compared to $82 thousand during the three
months ended September 30, 2002. On July 9, 2003 we closed a private placement
pursuant to Regulation S of the Securities Act, and sold 3,344,482 shares of our
common stock to Therfield Holdings LTD., a limited liability company formed
under the laws of the British Virgin Islands, for $1 million. Net cash provided
by financing activities for the three months ended September 30, 2003 was from
net cash provided from selling shares of common stock to Beach Boulevard, LLC
pursuant to an equity line of credit.
As a result of the foregoing, our net cash outflow increased by $756
thousand during the three months ended September 30, 2003, compared to a $268
thousand decrease in the three months ended September 30, 2002.
Cash and cash equivalents at September 30, 2003 were $1,200 thousand,
compared to $669 thousand at September 30, 2002.
As of November 1, 2003, our current monthly expense rate is under $300
thousand; our monthly expense rate at our former full operational level was
approximately $1,100 thousand. As of November 1, 2003, we had cash, accounts
receivable and pre-paid expenses of approximately $1,200 thousand and current
liabilities (excluding the debenture and deferred revenue) of approximately
$1,100 thousand. These current liabilities consist of approximately $547
thousand of accounts payable, $467 thousand of accrued liabilities, and $83
thousand of accrued employee costs. Accordingly, unless we are able to secure
additional funding from a third party, we do not currently have sufficient
working capital to sustain our operations, which are already substantially
reduced, beyond December 2003 or January 2004. Our failure to secure additional
funding may result in further severe reductions in our operations or the
discontinuance of our operations altogether.
24
The following table summarizes our contractual obligations and
commitments to make future payments as of September 30, 2003:
Payments due by period
----------------------
Total Less than 1 year 1-2 years After 3 years
----- ---------------- --------- -------------
Operating Leases $331,989 $198,385 $133,604 $ 0
Convertible debenture net of conversion privilege 0 0 -- --
Interest on Debenture 0 0 -- --
--------- --------- --------- ---------
Total $331,989 $198,385 $133,604 $ 0
========= ========= ========= =========
CAPITAL REQUIREMENTS/PLAN OF OPERATION
Our capital requirements may vary from our estimates and will depend
upon numerous factors including, but not limited to: a) FDA approval process; b)
results of pre-clinical and clinical testing; c) costs of technology; d) time
and costs involved in obtaining other regulatory approvals; e) costs of filing,
defending and enforcing any patent claims and other intellectual property
rights; f) the economic impact of developments in competing technology and our
markets; g) competing technological and market developments; h) the terms of any
new collaborative, licensing and other arrangements that we may establish; i)
litigation costs; and j) costs we incur in responding to inquiries and
investigations conducted by the Commission and other governmental entities.
Since inception, we have generated significant losses from operations
($93.9 million) and, although we have generated some revenues ($3.5 million), we
are still a development stage enterprise. We have taken actions to reduce our
expenses and cash consumption; however, we expect to incur additional operating
losses for the indefinite future. Our working capital requirements in the
foreseeable future will depend on a variety of factors and assumptions. In
particular, we will need to obtain additional financing through additional
equity and/or debt financings or through the sale of assets (including our
intellectual property) during fiscal year 2004. If we raise additional funds
through the issuance of equity securities or other financing instruments which
are convertible for equity securities, our shareholders may experience
significant dilution that would aversely affect the price of our common stock.
Furthermore, there can be no assurance that additional financing will be
available when needed or at all, or that if available, such financing will be on
terms favorable to us or our shareholders. If financing is not available when
required or is not available on acceptable terms, we may be required to curtail
our operating plan and will likely not be able to continue operations as a going
concern.
25
We do not have sufficient capital to cover: 1) the expected costs of
additional clinical studies as required by the FDA; 2) the potential damages of
pending shareholder litigation; or 3) the anticipated expense of funding our
business plan over the next year. We will have to obtain additional capital
within the fiscal year through issuance of securities, assumption of loans, sale
of assets (including our intellectual property). Furthermore, these factors have
made it difficult if not impossible to raise the required capital needed to
continue operations. If we are not successful, we will have to scale back our
business plans and may have to discontinue operations.
As of September 30, 2003, we believed that we had sufficient liquidity
to sustain current operations for next four to five months. Our monthly expense
rate at that time averaged $370 thousand, we had cash, marketable securities,
accounts receivable and pre-paid expenses of approximately $1.4 million and
current liabilities (excluding the debenture and deferred revenue) of
approximately $1.1 million. On a short term basis, we believed we would be able
to fund our operations with cash on hand and the proceeds of our receivables and
current sales activities; however, to fund our operations over the long term
(more than 6 months) we believed we would need to raise additional capital or
curtail our operation.
As of November 1, 2003, we have reduced operating expenses and
curtailed operating activities. Overall, we have reduced our monthly cash
consumption to under $300 thousand, which we currently believe will be adequate
to sustain our curtailed operations only through December 2003 or January 2004.
We have selectively reduced expenses by eliminating expenditures for certain
regional trade shows and conferences; reducing or eliminating administrative
staff, reducing purchased services and the level of certain employee benefit
programs, delaying salary increases and consolidating operations. If we are
unable to secure additional capital, we may need to further reduce our
operations or discontinue operations entirely.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK
We are a development stage enterprise. We believe we are not subject to
market risks beyond ordinary economic risks, such as interest rate fluctuation
and inflation.
At September 30, 2003, we had invested approximately $1.2 million in
cash and available-for-sale marketable securities including investments in
United States government securities and corporate bonds. Although we believe the
issuers of these marketable securities are solvent and are favorably rated by
recognized rating agencies, there is the risk that such issuers may not have
sufficient liquid assets to satisfy their obligations at the time such
obligations become due. If such were to occur, we may not be able to recover the
full amount of our investment.
Each of our marketable securities has a fixed rate of interest.
Accordingly, a change in market interest rates may result in an increase or
decrease in the market value of our marketable securities. If we liquidate any
of our marketable securities prior to the time of their maturity, we could
receive less than the face value of the security.
26
ITEM 4. CONTROLS AND PROCEDURES
(a) Based on the evaluation of our "disclosure controls and procedures"
(as defined in the Securities Exchange Act of 1934 Rules 13a-15(e) or 15d-15(e))
required by paragraph (b) of Rules 13a-15 or 15d-15, our chief executive officer
and our chief financial officer, have concluded that, as of September 30, 2003,
our disclosure controls and procedures were effective.
(b) There have been no changes in our internal control over financial
reporting identified in connection with the evaluation required by paragraph (d)
of Exchange Act Rules 13a-15 or 15d-15 that occurred during our last fiscal
quarter that have materially affected, or are reasonably likely to materially
affect, our internal control over financial reporting.
There have been no significant changes in our internal controls or in
other factors that could significantly affect these disclosure controls,
subsequent to the date of this evaluation.
PART II-- OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
SALAH AL-HASAWI ADVISORY SERVICES CLAIM
On March 29, 2000, Salah Al-Hasawi ("Plaintiff"), a citizen and
resident of Kuwait, filed an action in the U.S. District Court for the Southern
District of New York, against us and our former Chief Executive Officer,
alleging violations under Section 10(b) of the Securities Exchange Act of 1934
and Rule 10b-5 promulgated thereunder, for commissions allegedly due to the
plaintiff in connection with the private placement of our securities. Shortly
thereafter, the plaintiff's lawsuit was dismissed without prejudice and, on
April 12, 2000, the plaintiff filed a similar complaint in the United States
District Court for the District of Utah. The plaintiff has asserted that we
failed to pay him commissions of approximately $516,000 plus stock options to
purchase 1,070,000 shares of commons tock valued at $15 million, attorneys fees
and unspecified damages pursuant to five separate causes of action including
breach of contract, fraud and unjust enrichment.
We have denied all of the plaintiff's claims and have affirmatively
alleged that all amounts due have been paid in full. We are currently engaged in
the discovery process and an initial hearing has been scheduled for December 8,
2003. The likelihood of an unfavorable outcome or the extent of any potential
loss is not presently determinable.
27
SHAREHOLDER CLASS ACTION
Five separate lawsuits filed against us in the U.S. District Court in
Oregon alleged that CTI misled shareholders regarding such things as FDA
approval and other matters, which the plaintiffs asserted caused significant
damage to the holders of our common stock at the time of these alleged
misrepresentations and omissions. On September 24, 2002, the Court appointed a
lead plaintiff and consolidated these lawsuits into a single action; and on
November 5, 2002, the plaintiffs filed an amended consolidated complaint against
the Company and certain current and former officers. We filed a motion to
dismiss the litigation on December 19, 2002.
On April 17, 2003, the consolidated class action was dismissed without
prejudice by the U.S. District Court. In a written opinion, the U.S. District
Judge concluded that the alleged misstatements were either not material, not
misleading, or not pled by plaintiffs with sufficient particularity to
constitute a claim. The Court gave the plaintiffs until May 8, 2003 to replead
three of the nine claims. On May 8, 2003, the plaintiffs informed our counsel
that they would not replead any claims. Instead, the plaintiffs expressed their
intention to appeal the court's ruling following entry of the court's dismissal
order. That order was filed May 13, 2003, and the plaintiffs filed their notice
of appeal on May 20, 2003.
Our insurance carrier has denied coverage for the plaintiffs' claims
and, accordingly, has indicated it will not cover the costs of defending the
claims or pay any resulting damages we may suffer if the plaintiffs are
successful. We have retained counsel to evaluate the question of insurance
coverage regarding the plaintiffs claims set out in their amended consolidated
complaint. There can be no assurance that we will be successful in obtaining
insurance coverage for this litigation.
Under our bylaws and contractual agreements we may be required to
indemnify our current and former officers and directors who are parties to the
litigation by providing legal defense through our attorneys (or reimbursing them
for their own attorneys) and covering all damages they may suffer if the
plaintiffs are successful.
SEC INVESTIGATION
In December 2002, we were was requested to provide certain documents to
the Securities and Exchange Commission (the "Commission")and the U.S. Department
of Justice in connection with an investigation regarding possible violations of
the insider trading prohibitions found in the federal securities laws. We have
responded to the Commission's requests for copies of documentation, and members
of CTI management have provided testimony to the Commission. To date, we have
incurred approximately $650,000 in legal costs in complying with these requests.
CTI also may be required to indemnify its officers and directors in connection
with fees incurred in connection with these investigations. Our efforts to
respond to the Commission's requests have required, and in the future may
require, significant additional legal expenses, may make fund raising more
difficult if not impossible and will distract management from our day-to-day
operations.
28
ST. PAUL PROPERTIES
On April 11, 2003, St. Paul Properties, Inc. (the "Landlord") filed
suit against us in the Circuit Court for Clackamas County. The Landlord alleges
that we have breached our prior corporate office lease by failing to pay the
rent specified under the lease. The Landlord seeks damages of approximately
$667,000 plus interest and attorneys and other fees. The Company has filed an
answer and affirmative defenses alleging that St. Paul Properties failed to use
reasonable efforts to mitigate its damages. In addition, we are aware that much
of the vacant space has been relet to a third party tenant, substantially
reducing the damage claim. The Company has offered the sum of $40,000 to settle
the matter. That offer was rejected by the landlord, with no counter offer made
by the landlord. The Company intends to continue efforts to settle the matter.
INDEMNIFICATION
Under our bylaws and contractual agreements, CTI may be required to
indemnify its current and former officers and directors who are parties to
litigation or other proceedings by providing legal defense through the CTI
attorneys (or reimbursing the parties for their own attorneys) and covering all
damages the parties may suffer if the plaintiffs are successful.
OTHER LEGAL PROCEEDINGS
We are involved in certain other litigation matters in the normal
course of business which management currently believes are not likely to result
in any material adverse effects on our financial position, results of
operations, or net cash flows.
ITEM 2. CHANGES IN SECURITIES
On July 9, 2003, we closed a private placement under Regulation S of
the Securities Act, and sold 3,344,482 shares of common stock to Therfield
Holdings LTD., a limited liability company formed under the laws of the British
Virgin Islands, for $1 million. The shares of common stock sold in the private
placement were offered and sold in reliance upon the exemption for sales of
securities not involving a public offering, as set forth in Section 4(2) of the
Securities Act and Rule 506 promulgated under the Securities Act based upon the
following: (a) the investor represented and warranted that it was an "accredited
investor," as defined in Rule 501 of Regulation D promulgated under the
Securities Act and had such background, education, and experience in financial
and business matters as to be able to evaluate the merits and risks of an
investment in the securities; (b) there was no public offering or general
solicitation with respect to the offering, and the investor represented and
warranted that it was acquiring the securities for its own account and not with
an intent to distribute such securities; (c) the investor was provided with a
copy of our most recent Annual Reports on Form 10-K, Quarterly Reports on Form
10-Q and Current Reports on Form 8-K, and all other information requested by the
investor with respect to the Company, (d) the investor acknowledged that all
securities being purchased were "restricted securities" for purposes of the
Securities Act, and agreed to transfer such securities only in a transaction
registered with the Commission under the Securities Act or exempt from
29
registration under the Securities Act; and (e) a legend was placed on the
certificates and other documents representing each such security stating that it
was restricted and could only be transferred if subsequently registered under
the Securities Act or transferred in a transaction exempt from registration
under the Securities Act.
ITEM 3. DEFAULTS UPON SENIOR SECURITIES
Financing Agreement with Beach Boulevard, LLC.
On December 31, 2001, we entered into a financing agreement (the "Beach
Boulevard Agreement") with Beach Boulevard, LLC (the "Investor"), pursuant to
which we issued a 7% convertible debenture in the amount of $2.5 million (the
"Debenture Offering") and obtained an equity line of credit (the "Equity Line")
that enabled us to sell up to $20 million in common stock to the Investor at 94%
of the market price, as defined by the Beach Boulevard Agreement. The
convertible debenture was originally due on December 31, 2004. The terms of the
Beach Boulevard Agreement permits the Investor to convert the convertible
debenture into 2,100,694 shares of common stock at a conversion price of $1.44
per share at any time during the term of the Beach Boulevard Agreement. Interest
on the convertible debenture is due on the conversion date and is payable in
cash or common stock.
In connection with the Beach Boulevard Agreement, we entered into a
registration rights agreement and subsequently filed with the Commission a
Registration Statement on Form S-3, which was declared effective on March 18,
2002 (Registration No. 333-82016). Prior to completing the transactions
contemplated by the Beach Boulevard Agreement, we terminated our 1999 agreement
with the Investor to purchase up to $7 million of our common stock.
As of September 30 2003, we had satisfied all of our obligations set
forth in the Beach Boulevard Agreement. Over the life of the Beach Boulevard
Agreement a total of 26,487,821 shares of common stock were issued to the
Investor. Of those shares, 20,321,720 shares were issued to retire the
debenture, 3,764,321 shares were issued in connection with the equity line,
234,610 shares were issued upon the exercise of warrants, and 2,167,170 shares
were issued to satisfy interest and penalty obligations. The total cash we
received from the transactions associated with the Beach Boulevard Agreement
totaled $3,457,956 and the costs attributed to obtaining the debenture and
related credit line were approximately $438,696. On July 7, 2003 we issued
196,451 shares of common stock to the Investor, in order to satisfy $157,195 of
interest and penalty and to terminate the Beach Boulevard Agreement.
In order to pursue our existing plan of operations, we will have to
secure additional financing through the sale of equity, the incurrence of debt
or the sale of assets, including our intellectual property. There can be no
assurance that capital will be available from any source or, if available, that
the terms and conditions associated with such capital will be acceptable to us.
If we raise equity or debt capital, the sale of these securities could dilute
existing shareholders, and borrowings from third parties could result in assets
being pledged as collateral and could provide loan terms that could adversely
affect our operations and the price of the common stock.
30
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
(a) EXHIBITS
31.1 Certification of Chief Executive Officer
31.2 Certification of Chief Financial Officer
32.1 Certification of Chief Executive Officer
32.2 Certification of Chief Financial Officer
(b) REPORTS ON FORM 8-K
Current Report on Form 8-K filed July 11, 2003 (reporting our
completion of the Therfield Holdings LTD private placement and
the resignation of Dr. Simmons as a director of CTI).
Current Report on Form 8-K filed July 10, 2003 (reporting the
execution of the NanDa Thermal Medical Technology, Inc.
manufacturing/licensing agreement).
Current Report on Form 8-K filed September 5, 2003 (reporting
the filing of a brief in support of the plaintiff's appeal of
the U.S. District Court decision in the pending class action
proceeding against CTI).
Current Report on Form 8-K filed October 3, 2003 (reporting
the resignation of John M. Brenna as Chief Operating Officer
and a director of CTI).
Current Report on Form 8-K filed October 20, 2003 (reporting
the appointment of BJ Mendenhall as Chief Financial Officer of
CTI).
31
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned thereunto duly authorized.
COMPUTERIZED THERMAL IMAGING, INC.
(Registrant)
/s/Richard V. Secord
Dated November 19, 2003 -------------------------------
Richard V. Secord
Chairman & Chief Executive Officer
/s/BJ Mendenhall
Dated November 19, 2003 -------------------------------
BJ Mendenhall
Chief Financial Officer
32